Bank of America Corp DE Grows Stock Position in Intellia Therapeutics, Inc. $NTLA
Bank of America Corp DE increased its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 11.2% in the first quarter, now owning 1,381,703 shares valued at $17,713,000. Other institutional investors like Royal Bank of Canada and Arrowstreet Capital also significantly increased their positions. Despite insider sales from the CAO and an EVP, analysts have issued mixed ratings for NTLA, with a consensus "Hold" and a target price of $21.15.
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10.7% - Here's What Happened
Intellia Therapeutics (NASDAQ:NTLA) saw its stock price rise by 10.7% during mid-day trading on Wednesday, though with lower-than-average trading volume. The company reported quarterly revenue of $7.66 million, missing estimates, while its adjusted loss of $0.80 per share matched expectations. Analysts have a mixed sentiment on the stock, with an average "Hold" rating and a price target of $21.15.
Trending Industry Today: Intellia Therapeutics Leads Gains In Gene Editing Stocks
Intellia Therapeutics (NTLA) is leading gains among gene-editing stocks, marking a significant upward trend within the industry. This performance highlights a positive movement for the company and potentially the broader gene-editing sector. The article focuses on NTLA's strong market performance and its implications for the industry today.
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative?
Intellia Therapeutics reported a net loss of US$106.63 million in Q2 2026 and a six-month net loss of US$202.87 million, both reduced from the prior year. This reduction in losses, alongside progress in its gene-editing pipeline like the positive Phase 3 results for lonvo z, may influence investor perception regarding cost management and the company's financial risk. Despite ongoing cash burn, the investment narrative is bolstered by regulatory momentum for lonvo z and analyst forecasts projecting significant revenue and earnings by 2029.
Will Narrowing Six‑Month Losses Shape Intellia Therapeutics' (NTLA) Gene‑Editing Investment Narrative?
Intellia Therapeutics reported narrower six-month net losses and improved basic loss per share in Q2 2026, which may positively influence investor perception of its cost management. While ongoing cash burn and potential dilution remain risks, the progress of its gene-editing pipeline, especially promising Phase 3 results for lonvo z, is crucial for its investment narrative. The company's future success hinges on converting clinical data into regulatory approval and commercialization.
Wasatch Advisors LP Sells 134,215 Shares of Intellia Therapeutics, Inc. $NTLA
Wasatch Advisors LP significantly reduced its stake in Intellia Therapeutics Inc. by selling 134,215 shares, decreasing its holdings by 51.3%. Despite this, other institutional investors increased their positions in NTLA. The company currently holds a consensus "Hold" rating from analysts with an average price target of $21.15, and reported a Q2 loss of $0.80 per share, in line with estimates, though revenue missed expectations.
Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada
Royal Bank of Canada significantly increased its stake in Intellia Therapeutics (NASDAQ: NTLA) during the first quarter, now holding 465,499 shares worth approximately $5.97 million. The company reported a quarterly loss of $0.80 per share, meeting estimates, but revenue of $7.66 million missed expectations, declining 46.4% year over year. Institutional investors collectively own 88.77% of NTLA, and analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $20.85.
Intellia Therapeutics (NTLA) Could Be 50% Undervalued After Its Q2 2026 Earnings
Intellia Therapeutics (NTLA) reported Q2 2026 earnings, remaining in a loss-making position, though net loss and loss per share improved year-over-year. Despite recent stock volatility and a mixed long-term record, a narrative analysis suggests NTLA is approximately 50% undervalued with a fair value of $23.94, driven by expectations for its gene-editing pipeline and future approvals. However, the company faces significant risks including high R&D costs and reliance on trial outcomes, and its high P/S ratio indicates market expectations are already elevated.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% despite missing revenue forecasts in its latest quarterly report, with revenues of US$7.7m falling 41% short of expectations. Analysts have subsequently cut 2026 revenue estimates by a substantial amount to US$52.3m, although loss per share estimates remain steady at US$3.18. The average price target has also dropped 8.5% to US$23.94, reflecting concerns about the weaker revenue outlook and continued losses, and the company is expected to underperform the industry's revenue growth.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% following its latest quarterly results, despite revenues falling 41% short of expectations. Analysts have subsequently cut next year's revenue estimates significantly, while holding loss-per-share forecasts steady, leading to an 8.5% drop in the average price target to US$23.94. The company's revenue is now expected to decline by 23% by the end of 2026, underperforming the industry's projected 23% annual growth.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported And Analysts Have Been Cutting Their Estimates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recently reported its quarterly results, showing a significant revenue miss of 41% below analyst forecasts, though statutory losses were in line. Following these results, analysts have substantially cut next year's revenue estimates for Intellia Therapeutics by 12% to US$52.3m, while maintaining loss per share forecasts, and consequently, the average price target has fallen by 8.5% to US$23.94. The company is now expected to lag the wider industry's revenue growth, with its own revenues forecast to decline annually by 23% by the end of 2026.
Intellia Therapeutics (NTLA) Stock Rises As Pipeline Progress Lifts Sentiment
Intellia Therapeutics (NTLA) stock increased by 6.2% following its Q2 earnings report, signaling positive investor sentiment despite continued losses. The company's pipeline progress, particularly with Lonvo-z completing Phase 3 trials and Nex-z trials resuming, is driving optimism. While revenue declined and losses widened year-over-year, the narrowing loss per share and a cash pile providing runway into 2028 are key factors in the investment debate.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced inducement grants to eight new employees on August 1, 2026, consisting of 38,200 restricted stock units (RSUs) vesting over three years. These grants were made under Intellia's 2024 Inducement Plan and approved by the compensation committee as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing.
State Street (NTLA) stake: 9.23M Intellia Therapeutics shares in 13G filing
State Street Corporation has disclosed a significant stake in Intellia Therapeutics (NTLA), reporting beneficial ownership of 9,234,987 shares, which represents 6.8% of the outstanding common stock. The filing, a Schedule 13G, indicates that State Street, along with its investment advisory subsidiaries, holds shared voting power over 8,907,136 shares and shared dispositive power over all 9,234,987 shares. This disclosure provides transparency regarding State Street's passive investment in Intellia Therapeutics.
Intellia Therapeutics | SCHEDULE 13G: Others
This article states that Intellia Therapeutics has filed a SCHEDULE 13G form with the SEC. The filing is categorized under "Others," indicating the nature of the report. This type of filing typically discloses beneficial ownership of shares.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. announced that on August 1, 2026, it awarded inducement grants to eight new employees. These grants consisted of time-based restricted stock units (RSUs) for a total of 38,200 shares of Intellia’s common stock, vesting annually over three years, and were made under Intellia’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for employment with the biopharmaceutical company.
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
Revolution Medicines' pancreatic cancer drug daraxonrasib is seeing "significant demand" through a compassionate use program, leading analysts to raise sales projections. Intellia Therapeutics believes it has identified a genetic signature (HLA C*05:01 allele) linked to liver enzyme elevations in patients receiving its experimental gene editing treatment nex-z, potentially resolving a key safety concern. The article also provides updates on Arrowhead Pharmaceuticals' acquisition of a priority review voucher, a joint manufacturing facility between CSPC Pharmaceutical and AstraZeneca, and Vedanta Biosciences' new funding for a C. difficile trial.
Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ)
Evercore ISI upgraded Intellia Therapeutics (NTLA) to Outperform, citing promising new data on its rare-disease therapy, nex-z, developed in partnership with Regeneron (REGN). This upgrade led to a premarket rise in Intellia's stock on Friday.
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics (NTLA) reported progress in its gene-editing programs during Q2, including positive Phase III results for lonvo-z in hereditary angioedema (HAE) and resumed enrollment for nex-z in transthyretin amyloidosis. The company is preparing a BLA for lonvo-z, targeting FDA acceptance by late 2026 and potential U.S. launch in H1 2027. Intellia also discussed financial results, with $628.4 million in cash and equivalents, expecting to fund operations into at least 2028.
Intellia Therapeutics, Inc. Stock 12‑Month Price Target Cut to $25.56, Implies 133% Upside
Intellia Therapeutics, Inc.'s average 12-month price target has been adjusted to $25.56 from $25.88 by 16 analysts, with a range between $8 and $95. This new target suggests a potential upside of approximately 133% based on the August 5th closing price. Despite the slight target reduction, the consensus rating from 19 analysts remains a "Buy."
Intellia Therapeutics | 10-Q: Quarterly report
This document is the quarterly report (10-Q) filed by Intellia Therapeutics. Quarterly reports contain unaudited financial statements and provide a continuing view of the company's financial condition and results of operations.
Intellia Therapeutics Releases Q2 2026 Financial Results
Intellia Therapeutics, Inc. (NTLA) reported its Q2 2026 financial results, showing a narrower loss per share of -$0.80, which beat analyst estimates of -$0.82. Despite this, the company's collaboration revenue declined by 46.2% year-over-year to $7.7M, and it posted a net loss of $106.6M. Intellia continues to invest in its CRISPR-based therapeutics pipeline and is working to manage costs while advancing clinical programs.
Wedbush Adjusts Intellia Therapeutics Price Target to $12 From $17, Maintains Neutral Rating
Wedbush has revised its price target for Intellia Therapeutics (NTLA) down to $12 from $17, while keeping a Neutral rating on the stock. This adjustment follows the company's recent earnings report for the second quarter and six months ended June 30, 2026, where it reported a Q2 loss of $0.80 per share and revenue of $7.7 million. Intellia Therapeutics is a clinical-stage gene editing company developing CRISPR-based therapies for conditions like hereditary angioedema and transthyretin amyloidosis.
Intellia Therapeutics Inc earnings matched, revenue fell short of estimates
Intellia Therapeutics Inc (NASDAQ: NTLA) reported second-quarter earnings per share (EPS) that matched analyst estimates at $-0.80, but its revenue of $7.66 million fell short of the consensus estimate of $13.18 million. The company's stock price has declined by 22.14% over the last three months and 4.28% over the past year. InvestingPro rates Intellia Therapeutics Inc's financial health as "fair performance."
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) reported a Q2 loss of $0.8 per share, matching analyst expectations, but missed revenue estimates by 47.22% with $7.66 million. Despite outperforming the S&P 500 year-to-date with a 22% stock increase, the company currently holds a Zacks Rank #4 (Sell) due to an unfavorable earnings outlook. Investors are advised to monitor management's commentary and future earnings estimates.
Intellia Therapeutics reports Q2 2026 net loss of $106.6M, $628.4M cash; positive Phase 3 data for lonvo-z
Intellia Therapeutics reported a Q2 2026 net loss of $106.6 million and $628.4 million in cash. The company highlighted positive Phase 3 HAELO data for lonvo-z, showing an 87% reduction in attack rate for hereditary angioedema, and anticipates FDA acceptance for lonvo-z in H2 2026. Additionally, Intellia resumed enrollment for nex-z Phase 3 trials and identified an HLA allele associated with higher transaminase elevations, engaging regulators on this finding.
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $7.7M, Vs. FactSet Est of $13.0M
Intellia Therapeutics, Inc. (NTLA) announced its Q2 revenue of $7.7 million, significantly missing the FactSet estimate of $13.0 million. This earnings flash provides a quick update on the company's financial performance for the second quarter.
Form 8K Intellia Therapeutics Inc For: 6 August By Investing.com
This article announces that Intellia Therapeutics Inc. filed a Form 8K on August 6th. The brief notice from Investing.com indicates that the filing is relevant to the stock market. Intellia Therapeutics Inc. (NTLA) saw a slight increase of 1.32% in its stock value mentioned in the context of this filing.
Intellia plans first-half 2027 U.S. launch if FDA approves hereditary angioedema treatment
Intellia Therapeutics reported positive Phase 3 HAELO data for its hereditary angioedema treatment, lonvoguran ziclumeran (lonvo-z), showing an 87% reduction in attacks versus placebo and no serious adverse events. The company anticipates FDA acceptance of its Biologics License Application (BLA) in the second half of 2026 and plans for a potential U.S. launch in the first half of 2027. Intellia also provided updates on its nexiguran ziclumeran (nex-z) ATTR programs, including new genomic insights and expected enrollment completion for MAGNITUDE-2 in the second half of 2026, while confirming a cash runway into 2028.
Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales But Fairer On Broader Checks
Intellia Therapeutics (NTLA) stock has seen a significant 93% decline over five years, yet its current valuation on broader checks suggests a mixed picture. While it appears overvalued based on its Price-to-Sales (P/S) ratio compared to the biotech industry, the company passes about half of Simply Wall St's value checks. The article highlights that future value depends on the company's ability to commercialize its R&D pipeline and manage high development costs.
NTLA Looks 46.1% Undervalued on GF Value™ but Faces Price-to-Sales Challenges
Intellia Therapeutics Inc (NASDAQ: NTLA) is set to report Q2 2026 earnings, with a consensus EPS loss of $0.78 and an expected revenue decline. Despite a GF Value™ suggesting it's 46.1% undervalued, the company faces significant challenges including a high Price-to-Sales ratio compared to its historical median, persistent unprofitability, and negative cash flow. Insider selling and mixed guru activity highlight the speculative nature and execution risks associated with this gene-editing biotech firm.
Intellia Therapeutics(NTLA) Stock Options Chain | Quotes & News
This article provides quotes and news related to Intellia Therapeutics (NTLA) stock options chain. It serves as a resource for investors interested in the company's stock performance and options trading.
NTLA|Intellia Therapeutics Inc|Price:11.095|Chg%:+0.295
This article from TradingKey provides a comprehensive stock analysis of Intellia Therapeutics Inc (NTLA), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. The company, a clinical-stage gene editing firm, shows strong revenue growth, with institutional ownership being very high despite recent selling. Analysts currently rate NTLA as a Hold, with expectations for the stock price to trend down in the medium term.
Intellia Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 6
Intellia Therapeutics will host a conference call on August 6, 2026, to discuss its second quarter 2026 financial results. The company has not yet released the full content of the announcement, but the call is a standard procedure for publicly traded companies to report their financial performance to investors and the public. Further details regarding the financial results will likely be provided during the conference call.
Intellia Therapeutics (NTLA) Stock Looks Cheap After A 92% Fall Yet Expensive On Sales
Intellia Therapeutics (NTLA) stock has experienced a significant 92.2% decline over five years, leading to a mixed valuation picture. While recent FDA clinical holds on its MAGNITUDE trials have been lifted, supporting sentiment, the company still appears expensive on a sales basis with a P/S ratio of 23.0x, significantly higher than its fair P/S ratio of 0.2x according to Simply Wall St's model. The article suggests that a rich revenue multiple is priced in, reflecting optimism for its gene editing platform despite lingering execution and funding risks.
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second-quarter 2026 financial results and business updates. Interested parties can join via webcast or teleconference, with a replay available on the company's website. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing to develop treatments for severe diseases.
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics (Nasdaq: NTLA) announced it will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates. Interested parties can join via webcast or teleconference, with a replay available for 90 days on the company's website. Intellia Therapeutics is a clinical-stage biopharmaceutical company focused on CRISPR gene editing to develop treatments for severe diseases.
Intellia Therapeutics (NTLA) Stock Looks Cheap After A 92% Fall Yet Expensive On Sales
Intellia Therapeutics (NTLA) stock has experienced a significant 92.2% decline over the past five years, presenting a mixed valuation picture. While recent FDA clinical holds lifting for MAGNITUDE trials offer some positive sentiment, the company's valuation on a price-to-sales (P/S) basis still appears expensive compared to its biotech peers and industry average. The current stock price embeds substantial optimism for its gene editing platform, with a significant gap between its current P/S ratio and Simply Wall St's calculated fair P/S ratio.
Intellia Therapeutics Inc (NTLA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Intellia Therapeutics Inc's (NTLA) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents general financial information for NTLA, including its market capitalization.
NTLA|Intellia Therapeutics Inc|Price:10.730|Chg%:-0.370
This article provides a detailed company profile for Intellia Therapeutics Inc (NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies. It outlines the company's focus on developing treatments for genetic and autoimmune diseases, including its lead product candidates for ATTR amyloidosis and hereditary angioedema. The article also lists key financial data, company executives, and institutional shareholdings.
Form 4 Intellia Therapeutics Inc For: 24 July By Investing.com
This article reports on a Form 4 filing for Intellia Therapeutics Inc (NTLA) dated July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article does not provide specific details about the changes in holdings but indicates that NTLA's stock experienced a -3.33% change.
Intellia Therapeutics CFO sells $91,248 in stock By Investing.com
Intellia Therapeutics' CFO, Edward J. Dulac III, sold 8,111 shares of the company's common stock for $91,248. This "sell-to-cover" transaction was non-discretionary, meant to satisfy tax obligations upon restricted stock unit vesting. The stock has recently declined by 6%, but InvestingPro data suggests it may be undervalued, and various analysts have offered mixed ratings and price targets based on recent data from their HAELO study.
Intellia Therapeutics (NTLA) CFO logs 8,111-share sell-to-cover tax trade
Intellia Therapeutics' EVP and CFO, Edward J. Dulac III, executed a mandatory "sell-to-cover" transaction of 8,111 shares of common stock on July 22, 2026. This sale, at a weighted average price of $11.25, was conducted to satisfy tax withholding obligations arising from RSU vesting and was not a volitional trade. After the transaction, Dulac directly owns 148,175 shares of Intellia Therapeutics common stock.
Intellia Therapeutics Stock Short Interest Falls to 44.41%
The short interest in Intellia Therapeutics (NASDAQ:NTLA) saw a notable decrease during the first half of July, with a 44.41% drop to 5,500,000 shares. This translates to an average of 1.0 days to cover these positions, indicating a significant change in investor sentiment or trading activity.
Intellia Therapeutics Stock And 2 High Growth Shares With Strong Balance Sheets
This article identifies three high-growth companies—Intellia Therapeutics (NTLA), Insulet (PODD), and Hamilton Lane (HLNE)—that also possess strong balance sheets, as highlighted by Simply Wall St's "Healthy high growth potential" screener. Each company is analyzed for its operations, market cap, and key investment drivers, as well as potential risks. The article encourages investors to use Simply Wall St's tools to further identify and analyze similar opportunities.
Intellia Stock And 2 Growth Shares With Clear Earnings Upside
This article highlights three growth stocks—Intellia Therapeutics (NTLA), Insulet (PODD), and Hamilton Lane (HLNE)—identified by a "Healthy high growth potential" screener. These companies are characterized by strong earnings growth forecasts and solid financial positions. While each presents significant opportunities, they also carry distinct risks related to market competition, regulatory landscapes, and product reliance.
Intellia Therapeutics (NTLA) Resumes Key Trials, Is The Undervalued Case Still Convincing?
Intellia Therapeutics has resumed its MAGNITUDE and MAGNITUDE-2 trials after the FDA lifted clinical holds, allowing patient enrollment for its CRISPR programs to continue. Despite a recent share price decline, the stock is considered 51% undervalued with a fair value of $26.63, underpinned by improving financial discipline and projected revenue expansion. However, its high P/S ratio of 27.6x suggests the market has already priced in optimistic revenue outcomes.
Intellia stock downgraded by Wolfe Research on valuation concerns
Wolfe Research downgraded Intellia Therapeutics (NASDAQ:NTLA) to Underperform from Peerperform, setting a price target of $9.00 due to valuation concerns. The firm based its valuation on lonvo-z supporting the company if nex-z is written off, projecting lower cumulative revenue compared to consensus estimates. Intellia, however, recently presented positive Phase 3 clinical trial results for lonvo-z, leading other firms like Canaccord Genuity, H.C. Wainwright, and Citizens to reiterate Buy or Market Outperform ratings with higher price targets.
Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed
Intellia Therapeutics (NTLA) has seen its stock drop by 12.1% despite announcing positive Phase 3 results for its gene-editing therapy Lonvo-z and plans for a 2027 U.S. launch. The article attributes this paradox to investor concerns around funding needs, commercial execution, potential dilution from equity raises, and the risk of payer pushback on high-cost gene-editing treatments, even as the company projects significant revenue growth by 2029.
Intellia Therapeutics (NTLA) Could Be 37% Below Fair Value On Gene Editing Hopes
Intellia Therapeutics (NTLA) is drawing investor attention with its current stock price of $16.84, which analysts suggest could be 37% undervalued based on a fair value of $26.63, driven by its clinical-stage CRISPR pipeline and expanding market for gene editing therapies. Despite recent short-term price fluctuations, the long-term outlook focuses on potential revenue growth and profitability linked to demographic trends and genetic conditions. However, the company's high P/S ratio of 35.6x, significantly above industry averages, poses valuation risks if market sentiment shifts or clinical trials face setbacks.
